[CLSTR]
< Back to situation

[REVISION HISTORY]

Hims & Hers business expansion and regulatory navigation

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-14 16:01 UTC → 2026-09-21 06:49 UTC · added removed

Hims & Hers has pursued international expansion and product diversification while navigating significant regulatory and financial shifts. In August 2026, the telehealth company expanded into Australia following its acquisition of the digital health platform Eucalyptus. This move allowed the company to offer branded GLP-1 weight-loss drugs, sexual health medications, and cholesterol treatments, with plans to introduce a women’s health segment via the brand Juniper. By September 2026, the company reported strong financial performance, with Q2 2026 revenue reaching $753 million, representing a year-over-year increase of approximately 38% to 40%. 40%, supported by a subscriber base exceeding 2.5 million. However, this growth occurred alongside intensifying legal and regulatory challenges, including an FTC lawsuit regarding data privacy and FDA scrutiny of compounded GLP-1 drugs. challenges. In response addition to the FDA crackdown on compounded semaglutide, Hims & Hers transitioned from promoting scrutiny regarding compounded versions to establishing GLP-1 drugs—which prompted a strategic pivot toward a direct distribution partnership with Novo Nordisk to sell for branded Ozempic and Wegovy. Wegovy—the company is facing a Federal Trade Commission (FTC) lawsuit. The FTC alleges that Hims & Hers disclosed customer health data, utilized hard-to-cancel subscriptions, and bypassed real-time physician consultations. Hims & Hers has disputed these claims, characterizing the legal action as an attempt to ‘generate headlines at our expense.’ Furthermore, a securities fraud class action lawsuit has been filed against the company, alleging material misstatements regarding its privacy practices. Financial analysts have noted that while the company maintains strong operating momentum, risks remain concerning declining gross margins and the impact of lower-margin weight-loss treatments.

Versions

  1. 2026-09-21 06:49 UTC Hims & Hers business expansion and regulatory navigation
  2. 2026-09-14 16:01 UTC Hims & Hers business expansion and regulatory navigation

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.